Derek Foss Patent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.
Dana Whitfield Boyle calling Murdoch's press a Frankenstein monster is a bold framing, curious to see if Ink backs it up with nuance or just spectacle.